Benzinga  Sep 15  Comment 
Shares of Bruker Corporation (NASDAQ: BRKR) have declined by 9.64 percent year-to-date. Morgan Stanley’s Steve Beuchaw has initiated coverage of Bruker with an Equal-weight rating and price target of $21. Although benchmarking suggests...
Benzinga  Jun 1  Comment 
At the 63rd ASMS Conference on Mass Spectrometry & Allied Topics (ASMS), Bruker (NASDAQ: BRKR) announced the launch of the novel MALDI Tissuetyper solution, based on the new rapifleX MALDI-TOF Mass Spectrometry system. This Smart News Release...
TheStreet.com  May 21  Comment 
NEW YORK (TheStreet) -- Shares of Bruker were falling 11.4% to $19.68 on heavy trading volume Thursday after the medical research instrument maker announced the resignation of CFO Charles F. Wagner, Jr. Wagner will leave Bruker on June 12,...
Benzinga  May 21  Comment 
Prima Biomed Ltd. (NASDAQ: PBMD) shares dipped 29.95 percent to $4.14 following a 269.38 percent gain on Wednesday. China Information Technology, Inc. - Ordinary Shares (NASDAQ: CNIT) shares declined 23.01 percent to $5.52 after the company...
Market Intelligence Center  May 15  Comment 
After Thursday’s trading in Bruker BioSciences (BRKR) the algorithms behind MarketIntelligenceCenter.com's Artifical Intelligence Center picked out a trade that offers a 6.55% or 11.02% (for comparison purposes only), while providing 11.34%...
Market Intelligence Center  May 14  Comment 
The patented option trade-picking algorithms behind MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered call trade on Bruker BioSciences (BRKR) that includes 9.10% downside protection. Sell one contract of the...
Market Intelligence Center  Apr 7  Comment 
For a hedged play on Bruker BioSciences (BRKR), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Sep. '15 $20.00 covered call for a net debit in the $18.50 area. That is also the break-even stock price for the covered...
TheStreet.com  Mar 5  Comment 
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of Jim Cramer, TheStreet, Inc., or any of its contributors.  TheStreet Ratings quantitative algorithm evaluates over 4,300 stocks on...


Bruker Bioscience manufactures scientific instruments for companies in life science, pharmaceutical, biotechnology, clinical and molecular diagnostics research, as well as in materials and chemical analysis. It develops products that utilize magnetic resonance technologies, mass spectrometry technologies, gas chromatography technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology technology and infrared and Raman molecular spectroscopy technologies. They also manufacture superconducting materials and devices. Bruker Bioscience is a global company, but primarily sells it products in the Americas, Europe, and Asia. Due to the capital intense nature of its products customers may defer spending in tough economic years or to the last part of the year, leading to seasonality and unpredictable revenues.[1]

Business Growth

For 2010 the company reported revenue of $1,304.9 million, up 17.1% as compared to 2009. This increase was due to revenues attributable to recent acquisitions, increases in sales of its core technologies, particularly in magnetic resonance, X-ray and mass spectrometry, and an increase in demand for its low temperature superconducting wire.[1]

Trends and Forces

Bruker's revenues can fluctuate according to capital spending patterns of customers

Bruker's customers often stock up on lab consumables and equipment at the end of the year, when funding is abundant (for example, NIH funding is distributed to labs towards the end of the calendar year). They may also defer the purchase of capital intensive equipment in slow years such as the 2008 financial crisis. Bruker's revenues thus fluctuate throughout the year and are strongest in the last quarter of the calendar year. NIH funding is not completely stable, either - economic pressures may result in a stagnation of NIH funding, which has been growing at 2-3% in the past few years, but is not expected to increase in the near future. Bruker's customers from academic and government research labs are directly affected by the limitations of NIH grant funding; a lack of funding results in fewer laboratory product and equipment purchases and adversely affects Bruker's sales revenues.[1]


Bruker competes with many companies that have signifcantly more financial, technical, and marketing capabilities. To be successful it must create products that can compete based on technolgy, speed to market, and cost. Some of its toughest competitors include[1]:


  1. 1.0 1.1 1.2 1.3 Bruker BioSciences 2011 10k
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki